Summary
GLP-1 therapies are evolving beyond diabetes and obesity management into a multi-indication cardiometabolic drug platform, with expanding applications across cardiovascular disease, chronic kidney disease (CKD), metabolic dysfunction-associated steatohepatitis (MASH), and obstructive sleep apnea (OSA).
Oral GLP-1 therapies, including Novo’s semaglutide, Eli Lilly’s orforglipron, and Structure Therapeutics' aleniglipron, could drive market growth by improving convenience, adherence, and accessibility beyond injectable treatments.
The development pipeline is becoming increasingly competitive and diversified, with Eli Lilly’s retatrutide, a triple GLP-1...
